• (PLX AI) – Zealand Pharma shares rose 1.2 percent after positive early data on phase 1 trial of its BI 456906 obesity drug candidate.
  • • Patients involved in the study saw greater bodyweight reduction than placebo, with no unexpected safety issues, researchers said in an abstract for the Obesity Week conference
  • • Biggest weight loss was 13.7% after 16 weeks
  • • Full results will be presented at the conference in the first week of November

Quelle: PLX AI